Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles

Dixit, Nishu; Vaibhav, Kumar; Pandey, Ravi Shankar; Jain, Upendra Kumar; Katare, Om Prakash; Katyal, Anju; Madan, Jitender

doi:10.1016/j.biopha.2014.10.016

Cited by 73 publications

(45 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…colic acid-PLGA-b-Vitamin E TPGS copolymer, for controlled delivery of docetaxel were found to possess highest antitumor efficacy and cellular uptake efficiency when compared with poly(lactic-co-glycolic) acid (PLGA) nanoparticles and PLGA-b-TPGS nanoparticles [51]. Cisplatin, when entrapped in non-aggregated folic acid-conjugated gelatin nanoparticles to improve drug delivery for the treatment of cancer, has shown a higher cellular uptake of 81% when compared with cisplatin plain gelatin nanoparticles, which have 51% uptake [52]. Vivero-Escoto et al [53] synthesized phenanthridinium (oligonucleotide intercalator) functionalized mesoporous silica nanoparticles and found that the prepared nanoparticles have austere cell growth inhibition due to the binding of the phenanthridium group present on the peripheral surface to cytoplasmic oligonucleotides such as HeLa cell messenger RNAs.…”

Section: Systemic Versus Localized Drug Delivery Systemsmentioning

confidence: 99%

“…No.DrugType/composition of nanoparticlesCell lines/animal models/neoplasmReferences1.DocetaxelPoly( ɛ -caprolactoneco-lactide)-D-α-tocopheryl polyethylene glycol succinate nanoparticlesCervical cancer cells[50]2.DocetaxelColic acid-PLGA-b-Vitamin E TPGS copolymer–[51]3.CisplatinFolic acid-conjugated gelatin nanoparticles–[52]4.–Phenanthridinium (oligonucleotide intercalator)-functionalized mesoporous silica nanoparticlesHeLa cells[53]5.Bleomycin sulfateNanostructured lipid particlesCervical cancer cells[54]6.DoxorubicinPolynorbonene-cholesterol/poly(ethylene glycol)–[55]7.DoxorubicinMesoporous silica nanoparticlesHeLa cells[56]8.DocetaxelD-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-lactide) nanoparticlesXenograft BALB/c nude mice tumor model[57]9.DoxorubicinCyclodextrin-containing pH-sensitive poly(2-(dimethylamino) ethyl methacrylate) star polymer nanoparticles–[58]10.PaclitaxelPoly(γ-glutamic acid-maleimide-co-l-lactide)-1,2-dipalmitoylsn-glycero-3-phosphoethanolamine (γ-PGA-MAL-PLADPPE) copolymer-based nanoparticles–[59]11.DocetaxelPoly(lactide-co-glycolide) and pluronic F68C...…”

Section: Systemic Versus Localized Drug Delivery Systemsmentioning

confidence: 99%

See 1 more Smart Citation

Possible role of nanocarriers in drug delivery against cervical cancer

Gupta

2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

Introduction: Cervical cancer is the second most common cancer and the largest cancer killer among women in most developing countries including India. Although, various drugs have been developed for cervical cancer, treatment with these drugs often results in a number of undesirable side effects, toxicity and multidrug resistance (MDR). Also, the outcomes for cervical cancer patients remain poor after surgery and chemo radiation. Methods: A literature search (for drugs and delivery systems against cervical cancer) was performed on PubMed and through Google. The present review discuss about various methods including its current conventional treatment with special reference to recent advances in delivery systems encapsulating various anticancer drugs and natural plant products for targeting towards cervical cancer. The role of photothermal therapy, gene therapy and radiation therapy against cervical cancer is also discussed. Results: Systemic/targeted drug delivery systems including liposomes, nanoparticles, hydrogels, dendrimers etc. and localized drug delivery systems like cervical patches, films, rings etc. are safer than the conventional chemotherapy which has further been proved by the several drug delivery systems undergoing clinical trials. Conclusion: Novel approaches for the aggressive treatment of cervical cancer will optimistically result in decreased side effects as well as toxicity, frequency of administration of existing drugs, to overcome MDR and to increase the survival rates.

show abstract

Section: Systemic Versus Localized Drug Delivery Systemsmentioning

confidence: 99%

Section: Systemic Versus Localized Drug Delivery Systemsmentioning

confidence: 99%

Possible role of nanocarriers in drug delivery against cervical cancer

Gupta

2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

show abstract

“…202 This formulation is currently developed under the name NC-4016 (NanoCarrier Co., Ltd; Japan) and has reached phase I/II clinical evaluation. Gelatin nanoparticles 203 and nanogels 204 functionalized with folate receptor-targeting groups were also described as formulations to increase the intracellular uptake of cisplatin.…”

Section: Impaired Drug Uptakementioning

confidence: 99%

How can nanomedicines overcome cellular-based anticancer drug resistance?

2016

View full text Add to dashboard Cite

Despite the great progress in the field of cancer research, complete remission of cancer patients is a rarely seen outcome in clinics. The failure of a plethora of promising anticancer drugs is mostly due to the insurgence of multidrug resistance (MDR) phenomena with various factors, both physio-pathological and cellular, being responsible for their development. Over the past 40 years, the impressive progress in the nanotechnology field and its application in medicine (i.e., nanomedicine) enabled the development of novel cancer treatments with improved specificity and efficacy, mainly referring to the possibility to overcome MDR. However, the emergence of many nanomedicines defined in the literature as ''overcoming the resistance'' has resulted in very few of them eventually being approved for clinical application and reaching the marketplace (liposomal formulation of doxorubicin (Myocet s , Caelix s ) and paclitaxel nanoparticles (Abraxane s ), for instance). The capacity of nanomedicines to overcome physio-pathologicalbased resistance by enhancing drug accumulation at the tumor site via passive and ligand-mediated targeting has been largely reviewed in the past few years. This review will specifically focus on the cellular mechanisms involved in the MDR, which will be discussed with respect to the cellular site in which their action is exerted (that is, membrane, cytoplasm or nucleus). A complete overview of various nanomedicines designed to bypass or directly inhibit each of these specific resistance mechanisms will be offered.

show abstract

“…Among the various ligands researched so far, folate (FA) is one of the most promising candidates that showed immense potential to target cancer cell owing to its high affinity for folate receptors (FRs), which are normally over-expressed in various human carcinomas, such as cervix uteri, liver, breast, ovary, etc. (Dixit et al, 2015;. Therefore, FA-decorated NLCs were prepared and evaluated.…”

Section: Introductionmentioning

confidence: 99%

Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy

et al. 2015

View full text Add to dashboard Cite

Background: Cervical cancer chemotherapy calls for the efficiently delivery of anticancer drug into cancer cells by nanoparticles. In this study, folate (FA) modified, cisplatin (CIS)-loaded nanostructured lipid carriers (NLCs) were constructed and evaluated. Methods: FA containing polyethylene glycol (PEG)-distearoylphosphatidylethanolamine (DSPE) (FA-PEG-DSPE) was synthesized. FA-PEG-DSPE modified, CIS-loaded NLCs (FA-CIS-NLCs) were prepared. Their particle size, zeta potential, drug encapsulation efficiency (EE) and in vitro delivery behavior were evaluated. In vitro cytotoxicity study of FA-CIS-NLCs was tested in human cervix adenocarcinoma cell line (HeLa cells). In vivo anti-tumor efficacies of the carriers were evaluated on a mice-bearing cervical cancer model.

show abstract

Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles

Cited by 73 publications

References 47 publications

Possible role of nanocarriers in drug delivery against cervical cancer

Possible role of nanocarriers in drug delivery against cervical cancer

How can nanomedicines overcome cellular-based anticancer drug resistance?

Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy

Contact Info

Product

Resources

About